Why you are scratching skin that used to be perfectly comfortable – and the complete evidence-based approach to making it stop

The Itch That Arrives with the Transition

It begins in ways that are easy to dismiss. A patch of dry skin on the shin that cream does not quite resolve. An irritation around the bra line that appears in the evening. A scalp that has become inexplicably sensitive. Skin that once tolerated everything – fragrances, fabrics, cleansers used for years – now reacts to half of them. And then, for some women, something more persistent: a generalized itching that is worst at night, that has no visible rash, and that no amount of scratching reliably relieves.

Up to 64% of women in perimenopause and menopause experience pruritus, or chronic itching – making it one of the most prevalent skin symptoms of this transition. Yet it is rarely mentioned alongside hot flushes and mood changes, and many women do not connect it to their hormones at all – learning the association only when they raise it with a clinician who recognizes it immediately.

According to menopause specialist Dr. Sherry Ross, itching is a symptom many women overlook or do not immediately associate with menopause, often learning the connection only after discussing it with their doctor. Left untreated, menopause pruritus can dampen quality of life, as ongoing itching, especially in delicate areas such as the vulva, can lead to burning or soreness.

This article explains the complete biology of menopausal pruritus, maps the spectrum of where and how it presents, identifies the warning signs requiring clinical assessment, and provides the full evidence-based treatment hierarchy – from daily skincare practice to topical actives, prescription interventions, and systemic hormonal support.

Part 1: How Estrogen Loss Destroys the Skin Barrier

Estrogen as Skin Architect

The skin is one of the most estrogen-sensitive organs in the body. Estrogen receptors are distributed throughout the epidermis (the outer skin layers), the dermis (the deeper structural layer), the sebaceous glands, hair follicles, sweat glands, and the peripheral nerve endings within the skin. This means that when estrogen falls – as it does during perimenopause and menopause – the effects are not limited to one aspect of skin function. They are structural, hydration-related, barrier-related, neurological, and microbiological simultaneously.

During menopause, the function of the skin’s barrier can become compromised. Estrogen is critical in maintaining skin health by supporting hydration, elasticity, and collagen production.

The specific mechanisms through which estrogen loss produces pruritus are multiple and interacting:

Mechanism 1: Collagen Loss and Structural Thinning

Research published in Dermatoendocrinology shows that postmenopausal women can lose up to 30% of their skin collagen in the first five years following menopause, with skin thickness decreasing by 1.13% per year and collagen content declining by 2% annually.

Collagen is the structural protein that gives skin its thickness and resilience. As it falls, the skin becomes progressively thinner – less able to cushion mechanical stimuli (friction, pressure, touch) and less protected from the nerve endings that transmit itch signals. A thinner dermis means nerve endings closer to the surface, which means lower-threshold stimuli can trigger itch perception.

Mechanism 2: Reduced Hyaluronic Acid and Water-Binding Capacity

Lower estrogen means less hyaluronic acid production, reducing the skin’s ability to hold water. Hyaluronic acid is the primary water-binding molecule of the dermis – each molecule can hold up to 1,000 times its weight in water. When estrogen-dependent hyaluronic acid production falls, the dermis loses its water-retention capacity, and the skin becomes progressively dehydrated at the structural level.

This is not the surface dryness that an ordinary moisturizer resolves overnight. It is a deeper structural loss of hydration that requires consistent, sustained restoration.

Mechanism 3: Barrier Function Disruption – The Central Driver of Itch

The skin barrier – technically the stratum corneum, the outermost layer of the epidermis – is the most directly relevant structure to the experience of itch. It functions as a physical seal: keeping water in and irritants, allergens, and pathogens out. Its integrity depends on three components: corneocytes (the dead, keratin-filled cells forming the “bricks”), the lipid matrix between them (the “mortar” – primarily ceramides, cholesterol, and fatty acids), and the antimicrobial peptides that populate the surface.

Estrogen regulates all three. When estrogen falls, ceramide synthesis decreases, the lipid matrix thins and becomes less structurally coherent, and trans-epidermal water loss (TEWL) increases dramatically. The compromised barrier allows penetration of environmental irritants (detergents, fragrances, fabrics, cold air, dry heat) that would previously have been excluded, and it allows water to escape from the skin’s interior – producing the combination of dryness and sensitivity that characterizes menopausal pruritus.

A 2025 paper published in the scientific literature, Menopause, Menstrual Cycle, and Skin Barrier Function, confirmed that menopausal women show measurably elevated TEWL and reduced barrier integrity compared to premenopausal women of similar age – with a direct correlation between declining estrogen and barrier deterioration.

Mechanism 4: The Histamine Connection

Estrogen modulates histamine release from mast cells within the skin. Histamine is the primary neurochemical mediator of itch – it binds to H1 receptors on peripheral nerve C-fibers and activates the itch-scratch cycle. When estrogen falls, this modulation weakens and histamine release becomes easier to trigger. This is why some women with menopausal pruritus notice that their itch worsens in the evening (when histamine levels naturally peak), responds to antihistamines, and coincides with other histamine-sensitivity phenomena such as red wine intolerance and food sensitivities.

Mechanism 5: Reduced Sebum and Loss of the Natural Oil Film

Estrogen influences sebaceous gland activity. As it declines, sebum production decreases – removing the naturally occurring oil film that acts as a physical barrier against environmental desiccation and provides lipid replacement for the stratum corneum’s own lipid layer. The result is skin that cannot maintain its surface moisture even when adequately hydrated internally.

Mechanism 6: Nerve Sensitization – When the Itch Has No Rash

Many women with menopausal pruritus experience a characteristic variant: itching without visible lesion. No rash, no redness, no identifiable skin change – just the persistent urge to scratch. This is neuropathic or neurogenic pruritus, mediated by changes in peripheral nerve sensitization rather than by conventional skin pathology.

Estrogen receptors are present on the peripheral sensory nerve fibers (C-fibers) that transmit itch signals. When estrogen withdraws, these fibers can become sensitized – their activation threshold lowered so that innocuous stimuli (light touch, temperature change, mild pressure) register as itch. This neuropathic itch does not respond to standard moisturizers or barrier repair products in the same way that dryness-related itch does, and its management requires a different approach.

The Cortisol and Stress Amplifier

Stress and the hormonal stress response directly worsen itch. A 2024 paper in the Journal of Clinical Medicine confirmed the bidirectional relationship between stress and itch: stress activates mast cells to release histamine, sensitizes peripheral C-fibers, and promotes the neural-immune circuit through which psychological stress produces dermatological symptoms. The elevated cortisol of perimenopause – driven by HPA axis hyperreactivity following estrogen loss – creates a sustained pro-pruritic neurochemical environment.

Part 2: Where and How Menopausal Pruritus Presents

Menopausal itching is not uniform – it presents in distinct patterns that reflect the distribution of estrogen receptors and the regional vulnerability of different skin areas:

Generalized pruritus – diffuse, widespread itching without localization to a specific area. Worst at night (when histamine peaks and skin temperature rises), often associated with no visible skin change, and frequently aggravated by hot showers, exercise, and stress.

Forearm and shin pruritus – the extensor surfaces of the limbs are particularly prone to barrier disruption and dryness-related itch, driven by their low density of sebaceous glands and high TEWL exposure.

Scalp itching – the scalp is richly innervated and sebaceous gland-dependent. Reduced sebum and altered scalp microbiome composition (driven by the same pH and hormonal changes affecting body skin) produce scalp dryness, flaking, and itch that is frequently mistaken for dandruff but does not respond to antidandruff products alone.

Vulvar and perineal itching – one of the most distressing presentations and the one most likely to prompt clinical consultation. Vulvar pruritus in menopause is driven by the combination of tissue thinning, pH change, altered vaginal microbiome, and reduced mucosal lubrication that characterizes the genitourinary syndrome of menopause (GSM). It may occur as the primary symptom of GSM before dryness or dyspareunia become prominent, and it responds to different management (local estrogen or prasterone) than cutaneous pruritus.

Chest and breast skin – hormonally sensitive skin areas with high estrogen receptor density that become particularly reactive during perimenopause.

The “formication” variant – some women describe their itch as a crawling, tingling, or burning sensation – as if something were moving across or just below the skin surface. This is formication (not to be confused with infestation), a neurogenic itch variant that is specifically associated with the neuropathic sensitization of menopausal skin. It is not dangerous, but it is deeply uncomfortable and specifically indicates a neurogenic rather than a barrier-disruption-only mechanism.

Part 3: When Pruritus Requires Clinical Assessment

The majority of menopausal pruritus is hormonal and responds to the measures described below. However, persistent, severe, or atypically presenting itch requires clinical evaluation to exclude other causes:

Seek clinical assessment when:

• Itch is accompanied by a visible rash, hives, blistering, or spreading skin change – may indicate contact dermatitis, eczema, lichen sclerosis (a specific autoimmune condition affecting vulvar skin, requiring specific diagnosis and treatment), psoriasis, or urticaria
• Itch is predominantly on the inner wrists, between fingers, around the waist or ankles – the classic distribution of scabies, which is underdiagnosed in adults
• Itch is severe and not responding to standard measures after 4–6 weeks
• Itch is associated with significant systemic symptoms – jaundice, weight loss, night sweats independent of menopause, fatigue disproportionate to sleep disruption. Systemic pruritus without rash can indicate liver disease, chronic kidney disease, thyroid dysfunction, and – rarely – hematological conditions. These causes can first present in midlife and must be distinguished from hormonal pruritus
• Vulvar itch that is focal, persistent, and accompanied by skin color changes – white, pale, or scarred-appearing vulvar skin may indicate lichen sclerosis, which carries a small but real malignant risk without appropriate monitoring and treatment
• Any itch accompanied by a new, firm, persistent skin lesion – requires clinical inspection to exclude cutaneous malignancy

Blood tests useful in the clinical assessment of persistent unexplained pruritus: thyroid function (TSH), liver function tests (LFTs), renal function, full blood count, ferritin, vitamin D, and fasting glucose.

Part 4: The Evidence-Based Treatment Hierarchy

Foundation Layer: The Daily Skincare Protocol

The most important and most immediately accessible intervention for menopausal pruritus is a systematic, consistent skincare routine designed specifically for a compromised, estrogen-depleted skin barrier. This is not generic moisturizing advice – it is a targeted approach to barrier restoration.

Cleansing: The First and Most Damaging Step (When Done Wrong)

Standard bar soaps and many foaming gel cleansers have a pH of 8–10. Applied to skin with a normal pH of 4.5–5.5, they temporarily raise the surface pH by 2–3 points. This alkaline disruption is directly damaging to the lipid matrix of the stratum corneum – dissolving the ceramide-containing “mortar” and worsening the barrier defect that is driving itch.

The single most impactful cleansing change: switch to a pH-balanced, fragrance-free, non-foaming cleanser (syndet bar or gentle cream/gel wash formulated at pH 4.5–5.5). Use lukewarm – not hot – water. Hot water accelerates TEWL and strips the residual oil film. Limit bathing to 5–10 minutes. Pat dry, do not rub.

The Application Window: The 3-Minute Rule

Moisturizer applied within 3 minutes of bathing or washing – while the skin is still slightly damp – seals in the water that the stratum corneum has temporarily absorbed. This “occlusion window” is the highest-efficacy moment for barrier repair moisturization. Applications made on fully dry skin provide approximately 60% less moisture retention than applications made immediately post-bathing.

What the Moisturizer Must Contain

For menopausal pruritus specifically, the moisturizer composition matters more than the brand:

• Ceramides (1, 3, 6-II) – direct replacement for the depleted stratum corneum lipid matrix; the most evidence-supported topical ingredient for barrier repair
• Hyaluronic acid – restores the water-binding capacity reduced by estrogen loss at both surface and deeper levels
• Glycerin – a humectant that draws water from the dermis into the stratum corneum
• Niacinamide (5%) – stimulates ceramide synthesis, reduces TEWL, and has direct anti-itch properties through its effects on mast cell histamine release
• Colloidal oatmeal – FDA-recognized skin protectant with documented anti-inflammatory, anti-itch, and barrier-repair properties. Anti-inflammatory activities of colloidal oatmeal contribute to the effectiveness of oats in treatment of itch associated with dry, irritated skin. It forms a protective film over the skin surface, reduces keratinocyte inflammation, and directly inhibits histamine receptor signaling. Available in lotions, creams, and bath additives

Avoid in menopausal skin:

• Fragrances and essential oils (contact sensitizers on a compromised barrier)
• Alcohol as a primary ingredient (desiccates the stratum corneum)
• AHA exfoliants at high concentration (further disrupts barrier in already-fragile skin)
• Antibacterial soaps (disrupts the skin microbiome)

Body Oil Layer for Severe Dryness

For women with significant itch-producing dryness, applying a thin layer of plain emollient oil (coconut oil, sweet almond oil, or jojoba oil – all appropriate for itch-prone menopausal skin) before applying a ceramide moisturizer creates an additional occlusive layer that significantly slows TEWL. This “oil-then-cream” approach is particularly effective for the shin and forearm areas where dryness-related itch tends to be most severe.

Step 2: Targeted Topical Anti-Itch Interventions

Colloidal oatmeal – available as bath soaks (adding 1–2 cups of colloidal oatmeal to a lukewarm bath), leave-on lotions, and barrier creams. The bath soak format is particularly useful for generalized pruritus, as it treats the entire skin surface simultaneously. Evidence-supported, extremely well-tolerated, with no adverse effects.

Menthol (0.5–3%) – produces a cooling sensation via TRPM8 receptor activation that directly competes with and suppresses itch signal transmission along C-fibers. Available in many over-the-counter body lotions and cooling sprays. Provides immediate, temporary relief and is particularly useful for acute itch flares and the formication variant of neurogenic pruritus. Note: menthol should not be applied to broken, inflamed, or acutely irritated skin – the cooling sensation becomes a burning sensation on damaged skin.

Calamine lotion – zinc oxide and ferric oxide in a soothing aqueous suspension. Anti-inflammatory and mildly astringent. An old remedy with persistent clinical value for pruritic skin – particularly for chest and body itch where a thin, drying preparation is more comfortable than a heavy cream.

Aloe vera gel – contains polysaccharides with anti-inflammatory activity, acemannan (which supports barrier function), and salicylates (mild anti-inflammatory). Evidence for pruritus relief is modest but consistent in studies of itch associated with dry skin conditions. Best applied directly from the plant (inner gel of the leaf) or from 99%+ pure formulations without additives.

Step 3: Over-the-Counter Pharmacological Options

Topical hydrocortisone 1% – the most accessible prescription-strength-adjacent intervention for inflamed, itchy skin. Works by suppressing the local inflammatory response that drives histamine release and keratinocyte-mediated itch. Mild steroid creams, such as those with 1% hydrocortisone, can soothe inflammation and reduce irritation. For menopausal pruritus, appropriate for short courses (maximum 7 days in any one skin area) on acutely inflamed, visibly red, itchy patches. Not appropriate for continuous use – repeated application causes skin thinning, which worsens the very thinning that menopausal estrogen loss is already producing.

Oral antihistamines – first-generation (sedating) antihistamines (chlorphenamine, diphenhydramine) are most effective for histamine-mediated itch and have the additional benefit of improving sleep onset in women whose pruritus is worst at night. Second-generation (non-sedating) antihistamines (loratadine, cetirizine, fexofenadine) provide daytime itch control with less impairment. For menopausal pruritus with a clear histamine component (worsened by wine, certain foods, or evening timing), a brief trial of antihistamines provides good diagnostic information as well as symptomatic relief.

Step 4: Prescription Topical Options

Prescription-strength emollients – urea-containing preparations (10–25% urea) are keratolytic (dissolve abnormal surface cell accumulation) and humectant, with particularly strong evidence for chronic dry-skin-associated itch. At 10%, urea is hydrating and barrier-supporting; at 25%, it has additional keratolytic properties useful for severely thickened, very dry, persistently itchy skin. Available on prescription in most European healthcare systems.

Topical pimecrolimus (Elidel 1%) or tacrolimus (Protopic 0.03–0.1%) – calcineurin inhibitors that reduce local inflammatory signaling without the skin-thinning side effect of topical corticosteroids. Particularly valuable for perimenopausal skin where repeated steroid use is contraindicated by the already-present thinning from estrogen loss. Strong evidence for atopic dermatitis; evidence for use in other inflammatory pruritic conditions is growing. Appropriate for women with persistent itch on areas where steroid use is particularly concerning (face, genitals, skin folds).

Crotamiton cream (Eurax 10%) – direct anti-itch mechanism; inhibits C-fibre activity independently of antihistamine pathways. Useful for the neurogenic/formication variant of pruritus that does not respond well to moisturizers or antihistamines alone.

Topical doxepin – a tricyclic antidepressant that, applied topically, provides potent antihistaminergic and anti-itch effects at the skin surface. Licensed for pruritus in some countries; not appropriate for large body surface areas due to systemic absorption and drowsiness risk.

Step 5: Addressing Nutritional Deficiencies That Worsen Pruritus

Vitamin D – a 2024 meta-analysis published in the International Journal of Molecular Sciences evaluated the role of vitamin D in alleviating chronic pruritus and found evidence supporting vitamin D supplementation as a beneficial intervention for itch associated with inflammatory and dry skin conditions. Vitamin D regulates skin barrier gene expression and keratinocyte differentiation – deficiency directly impairs barrier function. Test and correct to above 50 nmol/L. At corrected levels, many women notice improvement in skin dryness and itch within 8–12 weeks.

Omega-3 fatty acids – EPA and DHA from oily fish or algae-based supplements reduce systemic inflammation, directly support the lipid composition of the stratum corneum, and have demonstrated anti-inflammatory effects on keratinocyte function. 2–3g EPA+DHA daily. The skin benefits of omega-3 supplementation build over 8–12 weeks of consistent intake.

Vitamin E – a fat-soluble antioxidant with direct skin membrane-stabilizing properties. Vitamin E protects skin cell membranes from oxidative damage, supports barrier lipid integrity, and has modest anti-itch properties in clinical studies. 400 IU daily from food or supplementation; food sources include almonds, sunflower seeds, and avocado.

Zinc – involved in keratinocyte function and skin barrier integrity. Deficiency produces dermatitis-like skin changes and impaired barrier repair. At 8–11 mg daily from food or supplementation as indicated by blood levels.

Hydration – systemic dehydration concentrates the blood, reduces skin tissue fluid, and worsens barrier function. A minimum of 2 liters of water daily is the baseline; additional fluid to compensate for losses from hot flushes and night sweats.

Step 6: Hormone Therapy – The Most Direct Intervention

For women with generalized menopausal pruritus driven by systemic estrogen loss, systemic hormone therapy addresses the primary cause at the molecular level. HRT often provides significant relief by restoring estrogen levels that support skin hydration and health.

Estrogen therapy restores:

• Ceramide synthesis and stratum corneum lipid matrix integrity
• Hyaluronic acid production and dermal water-binding capacity
• Collagen and elastin synthesis
• Sebaceous gland function and the surface oil film
• Peripheral nerve C-fiber activation threshold (raising the itch threshold)
• Skin microbiome composition through restoration of surface pH

Many women report that skin itch and dryness are among the first symptoms to improve after initiating MHT – typically within 4–8 weeks. For women already on MHT for vasomotor or mood symptoms, improving the formulation (ensuring adequate estrogen dose) often resolves persistent skin symptoms that have been incompletely addressed.

Topical vaginal estrogen for vulvar pruritus – vulvar itch driven by GSM requires local, not just systemic, hormonal treatment. Topical estrogen creams, vaginal suppositories, and vaginal rings deliver estrogen directly to the vulvovaginal tissues, restoring tissue thickness, pH, and microbiome balance – the three factors driving GSM-related pruritus. Vaginal estrogen treats localized symptoms without systemic hormone exposure. Vaginal estrogen creams, rings, and tablets effectively address vulvar and vaginal itching.

Step 7: Specialist Dermatological Management

For women with lichen sclerosis (the most important specific vulvovaginal skin condition to diagnose and treat), the first-line treatment is high-potency topical corticosteroid (clobetasol propionate 0.05%) applied in a defined protocol – not the short-term hydrocortisone appropriate for general itch. Lichen sclerosis requires formal dermatological or gynecological diagnosis, monitoring for disease control, and regular clinical review. It should not be managed solely with over-the-counter products.

For refractory generalized pruritus not responding to the above measures, specialist options include phototherapy (narrowband UVB – particularly effective for inflammatory pruritic conditions), dupilumab (a monoclonal antibody targeting IL-4 and IL-13 signaling, approved for atopic dermatitis and now used for other pruritic conditions), and low-dose naltrexone (an opioid receptor antagonist with emerging evidence for central itch modulation).

Part 5: Environmental and Lifestyle Modifications

Temperature regulation – hot showers and baths directly worsen pruritus by increasing TEWL, activating TRPV1 (heat-sensitive itch receptors in C-fibers), and vasodilating skin blood vessels (which transiently releases more histamine). Lukewarm water, brief bathing, and a cool bedroom at night all reduce the thermal activation of itch pathways.

Fabric choices – wool and rough synthetic fabrics provide mechanical itch stimulation to already-sensitized skin. Pure cotton, bamboo, and smooth silk against the skin reduce this mechanical trigger. This is particularly relevant for nightwear and bedding, where contact is prolonged.

Washing products – laundry detergent residue on clothing and bedding is a significant itch trigger in barrier-compromised skin. Non-biological, fragrance-free, dermatologically tested detergent reduces this chemical sensitization.

Stress management – given the bidirectional relationship between cortisol, mast cell activation, and histamine release confirmed in the 2024 Journal of Clinical Medicine paper, consistent stress-reduction practice (mindfulness, yoga, breathwork, adequate sleep) is a direct anti-pruritic intervention, not merely a general wellbeing recommendation.

Scratch cycle management – scratching produces short-term relief but causes barrier micro-trauma that worsens the underlying condition and triggers keratinocyte-mediated inflammatory itch signals. Where the urge to scratch is intense, substituting pressure (applying firm pressure to the area with the flat of the hand rather than scratching) or cold (applying a cold pack or cooling spray to the site) interrupts the scratch cycle without the trauma of scratching.

Part 6: The Practical Daily Protocol

Cleansing and bathing: Lukewarm water, 5–10 minutes maximum. pH-balanced, fragrance-free, non-foaming cleanser. Pat dry.

Immediately post-bathing (within 3 minutes): Apply body oil (coconut, jojoba, or sweet almond) to damp skin, then apply ceramide-rich moisturizer over the top while skin is still slightly damp. Focus on high-pruritus areas (shins, forearms, chest, scalp).

Actives: Niacinamide 5% serum to face and sensitive areas. Colloidal oatmeal lotion for generalized body itch. Menthol cooling lotion for acute flares.

Supplements: Vitamin D (dose based on blood level – target above 50 nmol/L). Omega-3 (2–3g EPA+DHA daily with meals). Vitamin E (400 IU daily).

Bedtime: Apply a thicker emollient (shea butter, urea 10% cream, or plain petroleum jelly) to the most persistently itchy areas before bed. Cool bedroom temperature. Cotton or bamboo nightwear.

If itch is not controlled with the above measures after 4–6 weeks: Seek clinical assessment. Discuss MHT. Request a dermatological opinion. Rule out systemic causes with targeted blood tests.

The Conclusion

Itchy skin during perimenopause and menopause is one of the most prevalent and most under-discussed symptoms of this transition. It is not a cosmetic inconvenience. It is a physiologically coherent consequence of estrogen’s withdrawal from a skin organ that depended on it for structural integrity, hydration, barrier function, sebum production, and nerve fiber regulation. In its severe forms, it disrupts sleep, limits social engagement, produces skin damage from scratching, and significantly affects quality of life.

Clinicians view menopausal itching as a hormonally influenced skin change and assess barrier health, infection risk in sensitive areas, underlying dermatologic conditions, and whether systemic or local hormone therapy may be appropriate.

The treatment hierarchy is well-established and genuinely effective: a barrier-repair skincare routine using ceramide-containing, fragrance-free, pH-balanced products is the foundation; targeted topical actives (colloidal oatmeal, niacinamide, menthol) provide additional symptomatic relief; nutritional support (vitamin D, omega-3, vitamin E) addresses the systemic deficiencies that worsen pruritus; and hormone therapy – systemic for generalized itch, local for vulvovaginal itch – directly addresses the primary hormonal cause.

You do not have to simply endure the itch. It has a mechanism. The mechanism has treatments. And your skin – given the right support – can be comfortable again.

For more useful articles and expert guidance, explore the Womeno app – your personal digital companion through the hormonal transition. Download the app HERE

Sources

1. Hone Health / Edge Editorial. Menopause, Itchy Skin (Pruritus) & Low Estrogen. honehealth.com. October 2025. (Citing: Cvjetković Nikoletić Đ et al. 2025; Shevchenko A et al. 2017; Nair PA, Journal of Mid-Life Health 2014)
2. Forhers.com / Switzer J MD FACOG (Medical Review). Itchy Skin During Perimenopause? Here’s What’s Going On. forhers.com. December 2025. (Citing: AAD 2025)
3. Winona Medical. Menopause & Itching: Causes and Treatments. bywinona.com. Updated March 2026. (Citing: Cvjetković Nikoletić Đ et al. 2025 – Menopause, Menstrual Cycle, and Skin Barrier Function)
4. Natural Cycles. Itchy Perimenopause Skin: Causes, Symptoms, & How to Treat. naturalcycles.com. January 2026. (Citing: Khalil NB et al. Stress and Itch, J Clin Med 2024; Reynertson KA et al. Colloidal oatmeal, JDD 2015; International Journal of Molecular Sciences 2024 – Vitamin D and Chronic Pruritus meta-analysis)
5. Twentyeight Health. Perimenopause and Itchy Skin: Causes, Treatment, and Prevention.twentyeighthealth.com. 2025.
6. Oova. Perimenopause Itchy Skin: Causes, Treatment, and Prevention. oova.life. September 2025. (Citing: Dermatoendocrinology – collagen loss data; Newson Health Survey 2024)
7. The Better Menopause. Menopause Itchy Skin: Causes and Treatments. thebettermenopause.com. December 2025.
8. Medical News Today. Menopause itching: Causes, types, home remedies, and treatments.medicalnewstoday.com. July 2023.
9. Menopause Care UK. Menopause & Itching: Causes & Treatment. menopausecare.co.uk. 2025.
10. Doctronic AI. Menopause and Itching Explained. doctronic.ai. April 2026.
11. Cvjetković Nikoletić Đ et al. Menopause, Menstrual Cycle, and Skin Barrier Function. 2025. (As cited in multiple sources above)
12. Khalil NB, Coscarella G, Dhabhar FS, Yosipovitch G. A Narrative Review on Stress and Itch: What We Know and What We Would Like to Know. Journal of Clinical Medicine. 2024;13(22):6854. doi:10.3390/jcm13226854
13. Reynertson KA et al. Anti-inflammatory activities of colloidal oatmeal (Avena sativa) contribute to the effectiveness of oats in treatment of itch associated with dry, irritated skin. Journal of Drugs in Dermatology. 2015;14(1):43–48. PMID:25607907
14. Kamp E, Ashraf M, Musbahi E, DeGiovanni C. Menopause, skin and common dermatoses. Part 1: Hair disorders (alopecia). Clinical and Experimental Dermatology. 2022;47(3):477–484. PMC10092469.
15. International Journal of Molecular Sciences. Evaluating the Role of Vitamin D in Alleviating Chronic Pruritus: A Meta-Analysis. 2024;25(18):9983. PMC11432943.
16. Nair PA. Dermatosis associated with menopause. Journal of Mid-Life Health. 2014;5(4):168–175. PMC4264279. doi:10.4103/0976-7800.145152
17. Shevchenko A et al. Causes, pathophysiology, and treatment of pruritus in the mature patient. Clinical, Cosmetic and Investigational Dermatology. 2017;10:475–490.
18. Farage MA, Miller KW, Berardesca E, Maibach HI. Clinical implications of aging skin: cutaneous disorders in the elderly. American Journal of Clinical Dermatology. 2009;10(2):73–86. doi:10.2165/00128071-200910020-00001
19. PMC12565178. Reconsidering Hormone Replacement Therapy: Current Insights on Utilisation in Premenopausal and Menopausal Women: An Overview. 2025.
20. NICE. Menopause: diagnosis and management. NG23. Updated November 2024. nice.org.uk